Videos

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.

In part 2 of their discussion on COVID-19 vaccine mandates, experts Ned Milenkovich, PharmD, and Ron Lanton III, Esq., discussed how provider status could impact potential legal issues around COVID-19 vaccine mandates.

Immune globulin subcutaneous (human), 20% solution (Cuvitru) is approved for primary immunodeficiency in patients 2 years of age and older.

Thomas Menighan, co-founder of PursueCare and the CEO Emeritus of the American Pharmacists Association, discusses a pharmacists role in National Recovery Month.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

With the recent announcement of federal COVID-19 vaccine mandates, in addition to private businesses potentially requiring vaccines for employees, pharmacies and other health care facilities could have questions about legal issues surrounding these mandates.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

Sophia Humphreys, PharmD, MHA, said data are continuing to evolve around the safety and recommendations of COVID-19 booster doses, especially for the vaccine from Pfizer and BioNTech.

Gemtesa (vibegron; Urovant Sciences) tablets are approved to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Pharmacy Times spoke with Dr. Bradley Monk, investigator for KEYNOTE-826, #LBA2, which was presented at the ESMO Congress 2021, about the study and its importance to the world of cervical cancer.

Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

Jason Ausili, PharmD, the Chief Clinical Officer of FDS Amplicare, discusses the impact on community pharmacies and patients of the recent announcement by the HHS regarding the amendment to the COVID-19 PREP Act.

Aaron Clark, DO, medical director of value based care at Ohio State University and clinical associate professor of family medicine, discusses vaccine hesitancy and racial disparities around flu vaccinations.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

A panel of experts from various settings in the pharmacy field discuss the application of cultural humility and their own experiences when providing culturally appropriate care to underserved or marginalized populations.

Lola Fashoyin-Aje, MD, MPH, associate director of Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence, discusses the importance of promoting inclusion of members of racial and ethnic minority groups in cancer drug trials.

Dupilumab (Dupixent) was approved in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Unlike other medications for chronic idiopathic constipation, prucalopride works by enhancing colonic peristalsis to increase bowel motility.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses whether the process may be similar in the future in terms of compounding pharmacies’ role in the administration of psychedelic drugs like psilocybin.

Harry Webster, RPh, a registered pharmacist at Walgreens and a member of the LGBTQIA+ community, discusses the impact of stigma associated with PrEP and HIV on patients seeking to treat or prevent HIV.

Michael Ganio, PharmD, MS, BCPS, FASHP, Senior Director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists, discussed the recent strains for hospitals due to the newest wave of COVID-19.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses how compounding pharmacies manage quality assurance when putting together ketamine dosages for patients.

Panelists share final thoughts and advice regarding the critical role pharmacy has played and continues to play in public health initiatives.

Christie Boutte, PharmD, RPh, also discussed how the FDA approval gives pharmacists more tools to encourage patients who may be hesitant about vaccination.

Pharmacy Times spoke with Ilisa Bernstein, APhA senior vice president, Pharmacy Practice and Government Affairs, about the latest FDA approval of the Pfizer-BioNTech COVID-19 vaccine.

Experts from Emory Healthcare and Winship Cancer Institute discuss the management of oncology patients by pharmacists within an NCI-designated comprehensive cancer center.

Doug Long, vice president of industry relations at IQVIA, and Scott Biggs, director of supplier services, discussed their session at the 2021 National Association of Chain Drug Stores (NACDS) Total Store Expo titled "Pharmaceutical Trends, Issues, and Forecasts."

In an interview with Pharmacy Times®, Guillermo Torre-Amione, MD, PhD, FACC, the chairman of Cardiol Therapeutics, discusses the potential use for CBD in hospitalized patients with COVID-19, as well as its therapeutic benefits in certain patients with cardiovascular disease.